Amyloid Protein Dynamics in Alzheimer's Disease

The accumulation and transformation of amyloid proteins form the central pathological hallmark of Alzheimer’s disease. Proteolytic processing of the amyloid precursor protein (APP) by β-secretase and γ-secretase generates amyloid-β (Aβ) peptides of varying lengths and modifications. These peptides can remain soluble, assemble into oligomeric intermediates, or deposit as insoluble fibrils within the brain parenchyma and cerebral vasculature. Soluble oligomers are now recognised as highly neurotoxic entities that disrupt synaptic function and trigger neuroinflammation. Meanwhile, diverse Aβ proteoforms, including N- and C-terminally truncated, post-translationally modified or pyroglutamylated variants, influence aggregation kinetics and spatial localisation, segregating into distinct plaque and vessel populations. Clearance pathways via enzymatic degradation, phagocytic uptake, and glymphatic flow are critical in modulating amyloid burden, but they become progressively impaired with age and disease progression. Current research seeks to link specific proteoform profiles with clinical phenotype, to refine biomarker strategies and to develop targeted interventions that modulate distinct stages of the amyloid cascade.

Research from Nature Portfolio

High-resolution mass spectrometry of Alzheimer’s disease brain tissue has revealed a remarkable diversity of Aβ proteoforms, encompassing over two dozen unique species with varying N- and C-terminal truncations. Intriguingly, canonical full-length Aβ constitutes a minority of total aggregates. N-terminally truncated forms predominate in insoluble plaque cores, whereas C-terminal truncations are enriched in soluble aggregates, highlighting distinct aggregation pathways. This segregation underscores the potential for proteoform-specific toxicity and suggests that therapeutic approaches must address a spectrum of Aβ variants rather than targeting a single peptide length. The findings offer a refined molecular map of amyloid heterogeneity and open avenues for proteoform-tailored diagnostics and treatments.

Amyloid Protein Dynamics in Alzheimer's Disease publication trend

The graph below shows the total number of articles in amyloid protein dynamics in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Amyloid precursor protein (APP): a membrane protein cleaved to release amyloid-β peptides.

Amyloid-β (Aβ) peptides: fragments of APP that aggregate into neurotoxic oligomers and fibrils.

Secretases: β-secretase and γ-secretase enzymes that sequentially cleave APP to produce Aβ.

N-terminal truncation: removal of initial amino acids from Aβ, yielding shorter and often more aggregation-prone variants.

Proteoforms: distinct molecular forms of a protein resulting from genetic, proteolytic or post-translational modifications.

Cerebral amyloid angiopathy (CAA): deposition of Aβ within cerebral blood vessel walls causing vascular dysfunction.

References

1. ADAMTS4 is involved in the production of the Alzheimer disease amyloid biomarker APP669-711. Molecular Psychiatry (2023).
2. Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome. Acta Neuropathologica (2024).
3. Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain. Scientific Reports (2017).
4. Truncated and modified amyloid-beta species. Alzheimer's Research & Therapy (2014).